Search
enfortumab vedotin (Padcev)
Indications:
- locally advanced or metastatic urothelial cancer (bladder cancer) unresponsive to previous treatment
Adverse effects:
- most common
- fatigue (50%)
- alopecia (49%)
- decreased appetite (44%)
- other
- rash (48%)
- peripheral neuropathy (50%)
- hyperglycenia (11%)
Mechanism of action:
- targets nectin-4
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
Related
bladder cancer
General
antineoplastic monoclonal antibody
References
- Susman E
MedPage Today. June 4, 2019
https://www.medpagetoday.com/meetingcoverage/asco/80226
- Petrylak D et al
EV-201: Results of enfortumab vedotin monotherapy for locally
advanced or metastatic urothelial cancer previously treated with
platinum and immune checkpoint inhibitors.
American Society of Clinical Oncology (ASCO) 2019; Abstract LBA4505.
- Bankhead C
Survival Boost in Bladder Cancer With Antibody-Drug Conjugate -
Four-month absolute improvement with enfortumab vedotin in previously treated disease.
MedPage Today February 12, 2021
https://www.medpagetoday.com/meetingcoverage/mgucs/91192